Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference
Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, will participate in the Jefferies 2025 Global Healthcare Conference in New York City from June 3-5, 2025. CEO Dave Lennon will deliver a company overview presentation on June 4, 2025, from 2:00-2:30 PM ET. The presentation will be available via webcast on the company's IR website and accessible for replay for approximately 30 days after the event.
Whitehawk Therapeutics (NASDAQ: WHWK), un'azienda specializzata in terapie oncologiche focalizzate sui trattamenti ADC per il cancro, parteciperà alla Jefferies 2025 Global Healthcare Conference a New York City dal 3 al 5 giugno 2025. Il CEO Dave Lennon terrà una presentazione panoramica sull'azienda il 4 giugno 2025, dalle 14:00 alle 14:30 ET. La presentazione sarà disponibile in webcast sul sito IR dell'azienda e potrà essere rivista in replay per circa 30 giorni dopo l'evento.
Whitehawk Therapeutics (NASDAQ: WHWK), una compañía de terapias oncológicas centrada en tratamientos ADC para el cáncer, participará en la Conferencia Global de Salud Jefferies 2025 en la ciudad de Nueva York del 3 al 5 de junio de 2025. El CEO Dave Lennon ofrecerá una presentación general de la empresa el 4 de junio de 2025, de 2:00 a 2:30 PM ET. La presentación estará disponible vía webcast en el sitio web de IR de la compañía y podrá verse en repetición durante aproximadamente 30 días después del evento.
Whitehawk Therapeutics (NASDAQ: WHWK)는 ADC 암 치료에 중점을 둔 종양학 치료제 회사로, 2025년 6월 3일부터 5일까지 뉴욕시에서 열리는 Jefferies 2025 글로벌 헬스케어 컨퍼런스에 참여합니다. CEO 데이브 레넌은 2025년 6월 4일 오후 2시부터 2시 30분(동부시간)까지 회사 개요 발표를 진행할 예정입니다. 발표는 회사 IR 웹사이트를 통해 웹캐스트로 제공되며, 행사 후 약 30일 동안 재생할 수 있습니다.
Whitehawk Therapeutics (NASDAQ: WHWK), une entreprise de thérapeutiques en oncologie spécialisée dans les traitements ADC contre le cancer, participera à la Jefferies 2025 Global Healthcare Conference à New York du 3 au 5 juin 2025. Le PDG Dave Lennon présentera un aperçu de l'entreprise le 4 juin 2025, de 14h00 à 14h30 (heure de l'Est). La présentation sera disponible en webcast sur le site IR de l'entreprise et pourra être visionnée en replay pendant environ 30 jours après l'événement.
Whitehawk Therapeutics (NASDAQ: WHWK), ein Unternehmen für onkologische Therapeutika mit Schwerpunkt auf ADC-Krebsbehandlungen, wird an der Jefferies 2025 Global Healthcare Conference in New York City vom 3. bis 5. Juni 2025 teilnehmen. CEO Dave Lennon wird am 4. Juni 2025 von 14:00 bis 14:30 Uhr ET eine Unternehmensübersicht präsentieren. Die Präsentation wird per Webcast auf der IR-Website des Unternehmens verfügbar sein und etwa 30 Tage nach der Veranstaltung als Wiederholung abrufbar sein.
- None.
- None.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact:
IR@whitehawktx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-to-present-at-the-jefferies-2025-global-healthcare-conference-302466333.html
SOURCE Whitehawk Therapeutics, Inc.
FAQ
When is Whitehawk Therapeutics (WHWK) presenting at the Jefferies Healthcare Conference 2025?
Who will be presenting for Whitehawk Therapeutics (WHWK) at the Jefferies Conference?
How can I watch Whitehawk Therapeutics' (WHWK) presentation at the Jefferies Conference?
What is Whitehawk Therapeutics' (WHWK) main business focus?
